Read + Share
Sudarson J. Commentary on "Risk-benefit stratification for immune checkpoint inhibitor
therapy in head and neck cancer based on immune-related adverse events and
treatment discontinuation using routine clinical indicators beyond PD-L1
expression". Oral Oncol 2026;181:108099.
PMID: 42556055
|
 |
|
